Bristol-Myers Squibb Company (BMY) Return on Assets (ROA): 8.41%
Is Bristol-Myers Squibb Company’s return on assets (ROA) high or low?
Bristol-Myers Squibb Company's return on assets (ROA) of 8.41% is 323% above its 5-year average of 1.99%, near the high end of its 5-year range (-9.66%–8.43%).
The return on assets (ROA) for Bristol-Myers Squibb Company (BMY) is 8.41% as of Wednesday, June 10, 2026. It is above its 12-month average by 1019.13% (-0.92%).
BMY Return on Assets (ROA) Chart
BMY Average Return on Assets (ROA) Chart
BMY Current vs Average Return on Assets (ROA) Chart
BMY Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
8.41%
RETURN ON ASSETS (ROA) AVG TTM
-0.92%
RETURN ON ASSETS (ROA) AVG 3Y
3.28%
RETURN ON ASSETS (ROA) AVG 5Y
1.99%
RETURN ON ASSETS (ROA) AVG 10Y
4.53%
RETURN ON ASSETS (ROA) AVG 15Y
5.57%
RETURN ON ASSETS (ROA) AVG 20Y
7.91%
CURRENT VS TTM AVG
+1019.13%
CURRENT VS 3Y AVG
+156.21%
CURRENT VS 5Y AVG
+322.61%
CURRENT VS 10Y AVG
+85.76%
CURRENT VS 15Y AVG
+51.07%
CURRENT VS 20Y AVG
+6.26%
BMY Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | — | 8.41% | -0.92% | 3.28% | 1.99% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 16.38% | 6.37% | 11.74% | 14.58% |
| CVS Health Corporation (CVS) | $125.16B | 1.16% | 1.25% | 1.93% | 2.38% |
| Medtronic plc (MDT) | $103.04B | 5.25% | 2.54% | 3.33% | 3.79% |
| Danaher Corporation (DHR) | $130.25B | 4.42% | 4.68% | 5.89% | 6.01% |
| Elevance Health Inc. (ELV) | $87.43B | 4.17% | 4.89% | 5.25% | 5.41% |
| Pfizer Inc. (PFE) | $146.36B | 3.61% | 3.75% | 6.08% | 7.08% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 14.81% | 13.09% | 12.00% | 11.68% |
| Cigna Corporation (CI) | $78.25B | 4.10% | 2.99% | 3.50% | 3.82% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 16.38% | 7.62% | 7.90% | 6.83% |
Asset Efficiency
ROA
8.4%
ROE
36.3%
Bristol-Myers Squibb Company Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Bristol-Myers Squibb Company (BMY)?
- The return on assets (ROA) for BMY stock is 8.41%.
- Is Bristol-Myers Squibb Company's return on assets (ROA) high or low?
- Bristol-Myers Squibb Company's return on assets (ROA) of 8.41% is 323% above its 5-year average of 1.99%, near the high end of its 5-year range (-9.66%–8.43%).
- What is the TTM average return on assets (ROA) for Bristol-Myers Squibb Company (BMY)?
- The TTM average return on assets (ROA) for BMY stock is -0.92%.
- What is the 3Y average return on assets (ROA) for Bristol-Myers Squibb Company (BMY)?
- The 3Y average return on assets (ROA) for BMY stock is 3.28%.
- What is the 5Y average return on assets (ROA) for Bristol-Myers Squibb Company (BMY)?
- The 5Y average return on assets (ROA) for BMY stock is 1.99%.
- What is the 10Y average return on assets (ROA) for Bristol-Myers Squibb Company (BMY)?
- The 10Y average return on assets (ROA) for BMY stock is 4.53%.
- What is the 15Y average return on assets (ROA) for Bristol-Myers Squibb Company (BMY)?
- The 15Y average return on assets (ROA) for BMY stock is 5.57%.
- What is the 20Y average return on assets (ROA) for Bristol-Myers Squibb Company (BMY)?
- The 20Y average return on assets (ROA) for BMY stock is 7.91%.
Bristol-Myers Squibb Company Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 7.83% |
| 2024-12-31 | -9.66% |
| 2023-12-31 | 8.43% |
| 2022-12-31 | 6.53% |
| 2021-12-31 | 6.40% |
| 2020-12-31 | -7.59% |
| 2019-12-31 | 2.65% |
| 2018-12-31 | 14.06% |
| 2017-12-31 | 3.00% |
| 2016-12-31 | 13.22% |
| 2015-12-31 | 4.93% |
| 2014-12-31 | 5.94% |
| 2013-12-31 | 6.64% |
| 2012-12-31 | 5.46% |
| 2011-12-31 | 11.25% |
| 2010-12-31 | 9.98% |
| 2009-12-31 | 34.22% |
| 2008-12-31 | 17.79% |
| 2007-12-31 | 8.27% |
| 2006-12-31 | 6.20% |
| 2005-12-31 | 10.66% |
| 2004-12-31 | 7.85% |
| 2003-12-31 | 11.32% |
| 2002-12-31 | 8.54% |
| 2001-12-31 | 17.38% |
| 2000-12-31 | 26.80% |
| 1999-12-31 | 24.35% |
| 1998-12-31 | 19.30% |
| 1997-12-31 | 21.40% |
| 1996-12-31 | 19.41% |
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner